TLDR

• VR in healthcare must be treated as a regulated digital technology, especially when it affects training, clinical decisions, or GxP‑relevant data and workflows.

• Value comes from immersive training, simulation, and clinical use, but scaling beyond pilots depends on validated performance, robust data integrity, and demonstrable real‑world impact versus existing methods.

• Governance-by-design is essential: VR should be integrated into QMS, with clear intended use, risk‑based validation, audit trails, and alignment to GxP data integrity expectations such as ALCOA+.

• When VR combines with AI (e.g. adaptive coaching), evaluators should scrutinise explainability, bias, safety nets, and how these systems plug into wider AI governance and security controls.

• Decision‑makers should map current VR pilots, classify them by patient and data risk, and define an evidence roadmap so VR moves from demo‑ware to inspection‑ready capability.

The buzz around virtual reality (VR) in healthcare is huge. From immersive surgical training to virtual clinical trials and rehab, VR is being sold as the next big step in how we deliver and experience care. But as pilots turn into production ambitions, regulators won’t care about slick demos. They’ll ask the same question they always do: Where’s the validated, auditable, risk‑controlled evidence that it’s safe and it works?

If you’re a chief data officer, digital transformation lead, or part of a regulatory or quality team working with AI in healthcare and life sciences, this is the moment to shift from experimentation to governance‑by‑design.

Virtual Reality in Healthcare: A Regulated Tool, Not a Toy

Virtual reality in healthcare has to be treated like a regulated digital technology, not a “nice‑to‑have” experience layer [1]. Whenever VR touches training, simulation, remote consultations, or clinical data, it influences real‑world decisions and outcomes.

If VR changes how staff are trained, regulators will ask whether that training is demonstrably equivalent—or better—than existing validated methods [2]. If VR is used to collect or present clinical data, it starts to look like part of a medical device or a GxP‑relevant system, with all the obligations that come with that [1, 5].

The simple rule: the more your VR environment affects decisions, safety, or regulated data flows, the more you need to design it as part of your regulated stack, right alongside your other AI solutions in healthcare [4].

Data Integrity and Validation in VR Environments

VR is great at immersion, presence, and engagement. Regulators, though, care about accuracy, completeness, traceability, and control [6]. In VR, those can slip very easily if you don’t design for them up front.

Ask yourself:

• What’s your source of truth? If VR is visualising patient, manufacturing, or trial data, there should be a clear, controlled interface between the VR app and your validated data stores. VR should consume from, and write back to, governed systems of record, not become a shadow database [5].

• How is data captured and logged? Actions in VR (choosing a dose, completing a manufacturing step) still need to be recorded as structured, time‑stamped events. Clicks, gestures, and gaze must maintain an audit trail that meets ALCOA+ expectations (Attributable, Legible, Contemporaneous, Original, and Accurate) [7].

• How do you validate the experience layer? The VR front-end must be validated as a client to ensure it renders information correctly without mis-scaled values and behaves under realistic network conditions [6].

GxP and Compliance: When VR Becomes GxP‑Relevant

Once VR is used for GMP, GCP, or GLP activities, such as manufacturing training or clinical trial simulations, it becomes a GxP‑relevant system [5, 6]. This puts it inside your usual computerised system lifecycle.

Key points to work through:

1. Define Intended Use Clearly: Is the VR tool used for mandatory qualified learning paths or showing real subject data? [2].

2. Use Risk‑Based Validation: Apply CSV (Computer Systems Validation) or CSA (Computer Software Assurance) logic. High-risk activities, like sterile-technique training, require deeper documentation than soft-skills coaching [5].

3. Qualify Your Vendors: Assess the supplier’s quality system and ensure they can provide documentation to support your validation [6].

Evidence: What Will FDA and EMA Expect?

Regulators are getting more familiar with AI and immersive tech, but their core expectations remain stable: risk‑based evidence [3, 4].

For training and simulation:

• Show it actually works: You must prove VR training is at least non-inferior to current methods regarding knowledge retention and procedural accuracy [8, 9].

• Show real‑world transfer: You need evidence that VR-trained staff perform more safely in the real world through pre- and post-comparisons [9].

For clinical or research use:

• Clarify risk classification early: If VR influences diagnosis or treatment, it may be classified as a medical device (SaMD), requiring clinical evaluation and cybersecurity protocols [1, 10].

• Cover human factors: You need evidence that risks like motion sickness or information overload are identified and mitigated [2].

Plugging VR into QMS and Digital Governance

VR cannot live as a side project. To scale, it must plug into your existing Quality Management System (QMS) [5]. This includes:

• Design and Change Control: Managing updates to VR modules.

• Security and Privacy: VR devices process sensitive data, including movement patterns and eye tracking, necessitating central device management and role-based access [4].

• Data Governance: VR outputs should be modelled in your data catalogue and governed like any other operational data [7].

When VR Meets AI: Safety Overlays and Extra Responsibilities

When you add machine learning for adaptive training or coaching agents, you are deploying AI solutions with an immersive UI [4]. This brings extra responsibilities:

• Explainable Behaviour: Users and auditors need transparency regarding why an AI adjusted a difficulty level or flagged an error [3].

• Bias and Fairness: You must monitor for patterns where the AI behaves differently based on a user’s movement style or demographics [3, 4].

• Safety Nets: AI inside VR should not be a single point of failure; clear escalation paths must be documented [4].

Who Should Care—and What to Do Next

For chief data officers and digital transformation leaders, VR is a visible test case: good governance will accelerate scale; weak governance will stall pilots.

The Starting Playbook:

1. Map where VR is being tested.

2. Classify each use case by risk to patients and data integrity.

3. Bring VR under existing QMS and AI governance from day one.

4. Define an evidence roadmap to move from pilot metrics to regulatory-grade substantiation.

Want to stay ahead of the curve? Discover our curated list to see how industry leaders are accelerating timelines, implementing AI solutions in healthcare and gaining a competitive edge. Follow us for more actionable AI insights shaping the future of life sciences and AI in healthcare.

References

1. U.S. Food and Drug Administration. Augmented Reality and Virtual Reality in Medical Devices. Center for Devices and Radiological Health. Published March 2025.

2. U.S. Food and Drug Administration. Augmented Reality and Virtual Reality Medical Devices – Discussion Paper. Published January 2025.

3. European Medicines Agency. Artificial Intelligence in Medicines Regulation – Reflection and Workplan. Published February 2025.

4. U.S. Food and Drug Administration. Artificial Intelligence and Machine Learning in Software as a Medical Device (SaMD). Digital Health Center of Excellence. Published May 2025.

5. Medicines and Healthcare products Regulatory Agency (MHRA). GxP Data Integrity Guidance and Definitions. Revision 1. Published March 2018.

6. World Health Organization. Guideline on Data Integrity for Inspection of GxP Laboratories and Manufacturers. Annex 4 to WHO Technical Report Series. Published 2021.

7. IntuitionLabs. ALCOA+ Principles: A Guide to GxP Data Integrity. Published January 2025.

8. Pulijala Y, et al. Effectiveness of Immersive Virtual Reality in Surgical Training: A Randomized Controlled Trial. J Oral Maxillofac Surg. Published 2018.

9. Lai YH, et al. Effectiveness of Virtual Reality in Training Operating Room Nurses on Robotic Surgery. Published April 2025.

10. Cureus. A Comprehensive Review of FDA‑Cleared Virtual Reality Technologies in Radiology. Published June 2025.